Cabozantinib in Progressive Medullary Thyroid Cancer | Zendy

Rossella Elisei | Zendy; Martin Schlumberger | Zendy; Stefan Müller | Zendy; Patrick Schöffski | Zendy; Marcia S. Brose | Zendy; Manisha H. Shah | Zendy; Lisa Licitra | Zendy; Barbara Jarząb | Zendy; В. С. Медведев | Zendy; Michael C. Kreißl | Zendy; Bruno Niederle | Zendy; Ezra E.W. Cohen | Zendy; Lori J. Wirth | Zendy; Haythem Ali | Zendy; Colin Hessel | Zendy; Yifah Yaron | Zendy; Douglas W. Ball | Zendy; Barry D. Nelkin | Zendy; Steven I. Sherman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cabozantinib in Progressive Medullary Thyroid Cancer

Author(s) -

Rossella Elisei,

Martin Schlumberger,

Stefan Müller,

Patrick Schöffski,

Marcia S. Brose,

Manisha H. Shah,

Lisa Licitra,

Barbara Jarząb,

В. С. Медведев,

Michael C. Kreißl,

Bruno Niederle,

Ezra E.W. Cohen,

Lori J. Wirth,

Haythem Ali,

Colin Hessel,

Yifah Yaron,

Douglas W. Ball,

Barry D. Nelkin,

Steven I. Sherman

Publication year - 2013

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2012.48.4659

Subject(s) - cabozantinib , medicine , medullary thyroid cancer , placebo , discontinuation , oncology , tyrosine kinase inhibitor , adverse effect , hazard ratio , cancer , gastroenterology , surgery , thyroid cancer , pathology , confidence interval , alternative medicine

Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular endothelial growth factor receptor 2, and rearranged during transfection (RET), demonstrated clinical activity in patients with medullary thyroid cancer (MTC) in phase I.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research